1. Risankizumab shows faster response in bio naïve than in bio‐experienced psoriatic patients.
- Author
-
Mastorino, L., Castelli, F., Stroppiana, E., Verrone, A., Ortoncelli, M., Susca, S., Boskovic, S., Passerini, S.G., Macagno, N., Cariti, C., Licciardello, M., Solaroli, C., Pertusi, G., Aragone, M.G., Baggini, G., Addese, C., Leporati, C., Peila, R., Giura, M.T., and Rossotto, G.
- Subjects
CLINICAL trials - Abstract
This is because bio-naïve patients are candidates for biological treatment with a higher PASI than bio-experienced patients who have taken risankizumab following initial secondary inefficacy. Bio-experienced patients achieved PASI90 less than bio-naïve (40.41% vs. 55%, I P i = 0.041) at 16 weeks, differences was also detected in PASI90, 75 and PASI < 3 at week 28 between the two populations (65% vs. 84%, 77% vs. 93% and 78% vs. 91%, I P i = 0.003, I P i = 0.001 and I P i = 0.011 respectively). Effect of Risankizumab on patient-reported outcomes in moderate to severe psoriasis: the UltIMMa-1 and UltIMMa-2 randomized clinical trials. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF